Monument Health Rapid City Hospital
- Type
- Teaching hospital
- Where
- RAPID CITY, SD
- Medicare CCN
- 430077
- Received
- $657,742 in 95 records, 2024 ($39,952 general, $617,789 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: MONUMENT HEALTH RAPID CITY HOSPITAL Fuzzy (name and state)
- Federal award recipient: MONUMENT HEALTH RAPID CITY HOSPITAL, INC. Fuzzy (name and state)
- Nonprofit: MONUMENT HEALTH RAPID CITY HOSPITAL INC Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 41 | $39,952 |
| 2024 | Research payment | 54 | $617,789 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Amgen Inc. | 4 | $261,190 | 2024 |
| Eli Lilly and Company | 9 | $180,961 | 2024 |
| CSL Behring | 3 | $55,720 | 2024 |
| AstraZeneca Pharmaceuticals LP | 4 | $42,416 | 2024 |
| AstraZeneca UK Limited | 1 | $16,745 | 2024 |
| PFIZER INC. | 12 | $16,700 | 2024 |
| Medtronic, Inc. | 5 | $14,653 | 2024 |
| Alnylam Pharmaceuticals Inc. | 4 | $11,192 | 2024 |
| Zimmer Biomet Holdings, Inc. | 4 | $8,988 | 2024 |
| Sterilmed, Inc. | 1 | $8,200 | 2024 |
| ZOLL Respicardia, Inc. | 5 | $6,360 | 2024 |
| Boston Scientific Corporation | 8 | $5,036 | 2024 |
| Linde Gas & Equipment Inc. | 15 | $4,950 | 2024 |
| AngioDynamics, Inc. | 1 | $4,800 | 2024 |
| Novo Nordisk Inc | 3 | $3,000 | 2024 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $2,997 | 2024 |
| Novo Nordisk AS | 1 | $2,328 | 2024 |
| MicroVention, Inc. | 1 | $2,000 | 2024 |
| E.R. Squibb & Sons, L.L.C. | 1 | $1,000 | 2024 |
| Tandem Diabetes Care, Inc. | 1 | $1,000 | 2024 |
| Lilly USA, LLC | 1 | $1,000 | 2024 |
| Insulet Corporation | 1 | $1,000 | 2024 |
| Abbott Laboratories | 1 | $1,000 | 2024 |
| Biosense Webster, Inc. | 1 | $1,000 | 2024 |
| Merck Sharp & Dohme LLC | 1 | $1,000 | 2024 |
| Novartis Pharmaceuticals Corporation | 1 | $1,000 | 2024 |
| Stryker Corporation | 1 | $973 | 2024 |
| Gilead Sciences, Inc. | 1 | $500 | 2024 |
| Medline Industries LP | 1 | $28 | 2024 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 54 | $617,789 |
| Space rental or facility fees (teaching hospital only) | 30 | $19,450 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 4 | $11,200 |
| Long term medical supply or device loan | 2 | $5,773 |
| Grant | 4 | $3,500 |
| Debt forgiveness | 1 | $28 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | Sterilmed, Inc. | $8,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | AngioDynamics, Inc. | $4,800 | Long term medical supply or device loan | In-kind items and services | VenaCure 1470 Pro Device, ET | 2024 | |
| 2024-12-31 | Stryker Corporation | $973 | Long term medical supply or device loan | In-kind items and services | ALTRIX Device, PATIENT HANDLING - PH | 2024 | |
| 2024-12-31 | Medline Industries LP | $28 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-12 | Medtronic, Inc. | $375 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2024 |
| 2024-12-12 | Medtronic, Inc. | $375 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2024 |
| 2024-12-11 | Medtronic, Inc. | $13,403 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2024 |
| 2024-12-06 | Alnylam Pharmaceuticals Inc. | $1,942 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2024 | |
| 2024-11-25 | Abbott Laboratories | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | FREESTYLE LIBRE 3 Device, Diabetes Care | 2024 | |
| 2024-11-12 | Novo Nordisk Inc | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-11-12 | Boston Scientific Corporation | $66 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_PI | ELEGANCE | 2024 |
| 2024-10-24 | Boston Scientific Corporation | $2,500 | Grant | In-kind items and services | Device, General - Therapies_PI | 2024 | |
| 2024-10-24 | Boston Scientific Corporation | $333 | Grant | In-kind items and services | Device, General - Therapies_EP | 2024 | |
| 2024-10-24 | Boston Scientific Corporation | $333 | Grant | In-kind items and services | Device, General - Therapies_EP | 2024 | |
| 2024-10-24 | Boston Scientific Corporation | $333 | Grant | In-kind items and services | Device, General - Therapies_EP | 2024 | |
| 2024-10-22 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, RESPIRATORY | 2024 | |
| 2024-10-18 | ZOLL Respicardia, Inc. | $3,832 | Research payment | Cash or cash equivalent | remede System Device, Respiratory | ZOLL Respicardia, Inc. Registry Study | 2024 |
| 2024-10-17 | Merck Sharp & Dohme LLC | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | VERQUVO Drug, CARDIOVASCULAR | 2024 | |
| 2024-10-17 | Novartis Pharmaceuticals Corporation | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LEQVIO Drug, Cardiology/Vascular Diseases | 2024 | |
| 2024-10-16 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, RESPIRATORY | 2024 | |
| 2024-10-11 | Biosense Webster, Inc. | $1,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-10-08 | Novo Nordisk Inc | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-10-08 | Boston Scientific Corporation | $268 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_PI | ELEGANCE | 2024 |
| 2024-10-04 | Alnylam Pharmaceuticals Inc. | $1,000 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2024 | |
| 2024-10-01 | PFIZER INC. | $1,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VYNDAQEL Drug, CARDIOVASCULAR | 2024 | |
| 2024-09-30 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, RESPIRATORY | 2024 | |
| 2024-09-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-09-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-09-27 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, RESPIRATORY | 2024 | |
| 2024-09-19 | Tandem Diabetes Care, Inc. | $1,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-09-17 | AstraZeneca Pharmaceuticals LP | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | BRILINTA Drug, Cardiovascular and Metabolism | 2024 | |
| 2024-09-05 | E.R. Squibb & Sons, L.L.C. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-09-03 | Eli Lilly and Company | $126,413 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION | 2024 | |
| 2024-08-21 | PFIZER INC. | $10,000 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | THE COMPASSHER2 TRIALS COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2POSITIVE BREAST CA | 2024 |
| 2024-08-19 | AstraZeneca Pharmaceuticals LP | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | WAINUA Drug, Cardiovascular and Metabolism | 2024 | |
| 2024-08-15 | Zimmer Biomet Holdings, Inc. | $1,584 | Research payment | Cash or cash equivalent | Persona Device, Knees | Persona Ti-Nidium Personalized Total Knee System | 2024 |
| 2024-08-15 | Lilly USA, LLC | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-08-08 | Novo Nordisk Inc | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-08-07 | Insulet Corporation | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-07-31 | AstraZeneca Pharmaceuticals LP | $40,066 | Research payment | Cash or cash equivalent | A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared with Dapaglif | 2024 | |
| 2024-07-15 | ZOLL Respicardia, Inc. | $1,046 | Research payment | Cash or cash equivalent | remede System Device, Respiratory | ZOLL Respicardia, Inc. Registry Study | 2024 |
| 2024-06-28 | CSL Behring | $53,970 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2024 | |
| 2024-06-27 | MicroVention, Inc. | $2,000 | Research payment | Cash or cash equivalent | WEB ANEURYSM EMBOLIZATION SYSTEM Device, NEUROLOGICAL PRODUCT | EVALUATION OF THE ROADSAVER STENT USED IN CONJUNCTION WITH THE NANOPARASOL EMBOLIC PROTECTION SYSTEM FOR CAROTID ARTERY | 2024 |
| 2024-06-25 | ZOLL Respicardia, Inc. | $500 | Research payment | Cash or cash equivalent | remede System Device, Respiratory | ZOLL Respicardia, Inc. Registry Study | 2024 |
| 2024-06-18 | Boston Scientific Corporation | $202 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_PI | ELEGANCE | 2024 |
| 2024-06-14 | Alnylam Pharmaceuticals Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | AMVUTTRA Drug, Genetic Disease | 2024 | |
| 2024-06-05 | Alnylam Pharmaceuticals Inc. | $7,250 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2024 | |
| 2024-05-30 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, RESPIRATORY | 2024 | |
| 2024-05-28 | Eli Lilly and Company | $6,347 | Research payment | In-kind items and services | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION | 2024 | |
| 2024-05-25 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, RESPIRATORY | 2024 | |
| 2024-05-02 | Gilead Sciences, Inc. | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-05-02 | AstraZeneca Pharmaceuticals LP | $350 | Research payment | Cash or cash equivalent | FARXIGA Drug, Cardiovascular and Metabolism | Dapagliflozin in Acute Decompensated Heart Failure | 2024 |
| 2024-04-20 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, RESPIRATORY | 2024 | |
| 2024-04-20 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, RESPIRATORY | 2024 | |
| 2024-04-19 | Amgen Inc. | $91,455 | Research payment | Cash or cash equivalent | OCEANa-Outcomes P3 CV | 2024 | |
| 2024-04-19 | Amgen Inc. | $33,649 | Research payment | Cash or cash equivalent | Repatha Biological, Cardiology | 20170625_VESALIUS - CV | 2024 |
| 2024-04-19 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, RESPIRATORY | 2024 | |
| 2024-04-15 | ZOLL Respicardia, Inc. | $689 | Research payment | Cash or cash equivalent | remede System Device, Respiratory | ZOLL Respicardia, Inc. Registry Study | 2024 |
| 2024-04-11 | Zimmer Biomet Holdings, Inc. | $4,500 | Research payment | Cash or cash equivalent | Persona Device, Knees | Persona Ti-Nidium Personalized Total Knee System | 2024 |
| 2024-04-11 | Zimmer Biomet Holdings, Inc. | $1,320 | Research payment | Cash or cash equivalent | Persona Device, Knees | Persona Ti-Nidium Personalized Total Knee System | 2024 |
| 2024-04-05 | Eli Lilly and Company | $19 | Research payment | In-kind items and services | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2024 | |
| 2024-04-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | $997 | Research payment | Cash or cash equivalent | Phase II dose finding/PoCC in CKD | 2024 | |
| 2024-04-03 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, RESPIRATORY | 2024 | |
| 2024-03-29 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, RESPIRATORY | 2024 | |
| 2024-03-22 | Eli Lilly and Company | $1,988 | Research payment | Cash or cash equivalent | A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | 2024 | |
| 2024-03-21 | Zimmer Biomet Holdings, Inc. | $1,584 | Research payment | Cash or cash equivalent | Persona Device, Knees | Persona Ti-Nidium Personalized Total Knee System | 2024 |
| 2024-03-19 | Medtronic, Inc. | $250 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2024 |
| 2024-03-19 | Medtronic, Inc. | $250 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2024 |
| 2024-03-15 | CSL Behring | $1,000 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2024 | |
| 2024-03-15 | CSL Behring | $750 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2024 | |
| 2024-03-11 | Boston Scientific Corporation | $1,000 | Research payment | Cash or cash equivalent | General - Brady Device, General - Brady_CRM | APPRAISE ATP | 2024 |
| 2024-02-16 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, RESPIRATORY | 2024 | |
| 2024-02-15 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-02-15 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-02-15 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-02-15 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-02-15 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-02-15 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-02-15 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-02-15 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-02-15 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-02-15 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-02-13 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, RESPIRATORY | 2024 | |
| 2024-02-12 | Eli Lilly and Company | $2,750 | Research payment | Cash or cash equivalent | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2024 | |
| 2024-02-05 | Eli Lilly and Company | $14,683 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PL | 2024 | |
| 2024-01-30 | Eli Lilly and Company | $20,851 | Research payment | Cash or cash equivalent | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU | 2024 | |
| 2024-01-25 | Eli Lilly and Company | $2,940 | Research payment | In-kind items and services | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU | 2024 | |
| 2024-01-24 | Novo Nordisk AS | $2,328 | Research payment | Cash or cash equivalent | Rybelsus Drug, Diabetes | NN9924-4437 | 2024 |
| 2024-01-24 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, RESPIRATORY | 2024 | |
| 2024-01-17 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, RESPIRATORY | 2024 | |
| 2024-01-12 | AstraZeneca UK Limited | $16,745 | Research payment | Cash or cash equivalent | A Phase IIB Randomized Double blinded Placebo controlled Parallel group Study to Evaluate the Efficacy and Safety of MED | 2024 | |
| 2024-01-12 | ZOLL Respicardia, Inc. | $292 | Research payment | Cash or cash equivalent | remede System Device, Respiratory | ZOLL Respicardia, Inc. Registry Study | 2024 |
| 2024-01-08 | Amgen Inc. | $118,227 | Research payment | In-kind items and services | Repatha Biological, Cardiology | 20170625_VESALIUS - CV | 2024 |
| 2024-01-08 | Amgen Inc. | $17,858 | Research payment | In-kind items and services | OCEANa-Outcomes P3 CV | 2024 | |
| 2024-01-02 | Eli Lilly and Company | $4,970 | Research payment | Cash or cash equivalent | A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Rapid City, SD, county Pennington County, SD, state South Dakota; placed by its city name.
| Measure | Place (city or town) Rapid City, SD | County Pennington County, SD | State South Dakota |
|---|---|---|---|
| Population B01003 | 77,946 | 113,512 | 907,428 |
| Population, 2020 census P1 | 74,703 | 109,222 | 886,667 |
| Median age B01002 | 39.1 | 40.1 | 38.0 |
| Under 18 B01001 | 22.0% | 22.0% | 24.2% |
| 65 and over B01001 | 20.7% | 20.1% | 18.0% |
| Households B11001 | 32,368 | 46,370 | 365,544 |
| Foreign born B05002 | 2.6% | 2.5% | 4.0% |
| Median household income B19013 | $70,870 | $74,517 | $75,081 |
| Median family income B19113 | $91,802 | $92,479 | $96,562 |
| Per capita income B19301 | $42,204 | $42,302 | $40,550 |
| Poverty rate B17001 | 12.5% | 11.2% | 11.9% |
| Unemployment rate B23025 | 2.6% | 3.2% | 2.9% |
| Civilian labor force B23025 | 39,452 | 57,369 | 475,223 |
| Mean commute (minutes) B08013 | 17.5 | 19.4 | 17.8 |
| Bachelor's degree or higher B15003 | 37.0% | 34.6% | 31.9% |
| Housing units B25001 | 35,577 | 51,681 | 408,584 |
| Owner-occupied B25003 | 62.9% | 69.3% | 68.6% |
| Renters B25003 | 37.1% | 30.7% | 31.4% |
| Median home value B25077 | $299,400 | $302,200 | $257,400 |
| Median gross rent B25064 | $1,109 | $1,120 | $946 |
| White, not Hispanic B03002 | 76.3% | 77.8% | 79.8% |
| Black B03002 | 1.2% | 1.1% | 2.1% |
| Hispanic or Latino B03002 | 6.1% | 5.7% | 4.8% |
| Asian B03002 | 1.3% | 1.2% | 1.4% |
| American Indian and Alaska Native B03002 | 7.1% | 6.0% | 7.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Rapid City, SD.
Comments